Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Arrowhead Pharmaceuticals's cash was $1.60B at Jun 30, 2026. For fiscal 2025 it was $919.37M, up 35.0% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $919.37M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $919.37M | +35.0% |
| FY2024 | Sep 30, 2024 | $680.96M | +68.7% |
| FY2023 | Sep 30, 2023 | $403.63M | +273.7% |
| FY2022 | Sep 30, 2022 | $108.01M | -65.3% |
| FY2021 | Sep 30, 2021 | $311.16M | +36.1% |
| FY2020 | Sep 30, 2020 | $228.60M | +3.1% |
| FY2019 | Sep 30, 2019 | $221.80M | +636.1% |
| FY2018 | Sep 30, 2018 | $30.13M | +21.3% |
| FY2017 | Sep 30, 2017 | $24.84M | -70.9% |
| FY2016 | Sep 30, 2016 | $85.37M | +5.1% |
| FY2015 | Sep 30, 2015 | $81.21M | -47.3% |
| FY2014 | Sep 30, 2014 | $154.16M | +447.8% |
| FY2013 | Sep 30, 2013 | $28.14M | +707.9% |
| FY2012 | Sep 30, 2012 | $3.48M | -57.2% |
| FY2011 | Sep 30, 2011 | $8.14M | +18.9% |
| FY2010 | Sep 30, 2010 | $6.85M | +238.9% |
| FY2009 | Sep 30, 2009 | $2.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $1.60B | +77.9% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.78B | +62.6% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $916.61M | +65.8% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $919.37M | +35.0% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $900.37M | +106.2% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $1.10B | +109.8% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $552.94M | +151.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $680.96M | +68.7% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $436.67M | +314.6% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $523.11M | +287.6% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $220.28M | +8.9% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $403.63M | +273.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $105.33M | -24.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $134.96M | -35.4% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $202.25M | -7.1% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $108.01M | -65.3% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $139.44M | -69.2% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $208.98M | -58.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $217.60M | -3.7% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $311.16M | +36.1% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $452.39M | +106.3% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $498.17M | +94.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $225.93M | -51.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $228.60M | +3.1% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $219.32M | +16.5% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $256.65M | +58.8% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $461.03M | +142.9% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $221.80M | +636.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $188.33M | +572.7% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $161.64M | +131.6% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $189.77M | +1545.7% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $30.13M | +21.3% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $28.00M | -27.1% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $69.81M | +13.1% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $11.53M | -88.7% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $24.84M | -70.9% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $38.38M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $61.72M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $102.11M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $85.37M | – |
See a number that looks wrong?